Success Metrics

Clinical Success Rate
89.5%

Based on 17 completed trials

Completion Rate
89%(17/19)
Active Trials
0(0%)
Results Posted
18%(3 trials)
Terminated
2(9%)

Phase Distribution

Ph phase_3
5
23%
Ph phase_1
1
5%
Ph not_applicable
4
18%
Ph phase_2
5
23%
Ph phase_4
7
32%

Phase Distribution

1

Early Stage

5

Mid Stage

12

Late Stage

Phase Distribution22 total trials
Phase 1Safety & dosage
1(4.5%)
Phase 2Efficacy & side effects
5(22.7%)
Phase 3Large-scale testing
5(22.7%)
Phase 4Post-market surveillance
7(31.8%)
N/ANon-phased studies
4(18.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

89.5%

17 of 19 finished

Non-Completion Rate

10.5%

2 ended early

Currently Active

0

trials recruiting

Total Trials

22

all time

Status Distribution
Completed(17)
Terminated(2)
Other(3)

Detailed Status

Completed17
unknown3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
22
Active
0
Success Rate
89.5%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (4.5%)
Phase 25 (22.7%)
Phase 35 (22.7%)
Phase 47 (31.8%)
N/A4 (18.2%)

Trials by Status

unknown314%
completed1777%
terminated29%

Recent Activity

Clinical Trials (22)

Showing 20 of 22 trialsScroll for more
NCT00537810Phase 4

Treatment of Binge Eating in Obese Patients in Primary Care

Completed
NCT01170364Phase 4

Studying the Effects of Sibutramine on Eating Behavior

Terminated
NCT01597609Phase 1

A Study to Characterise the Physiology of Weight Loss and Regain Under Dietary, Behavioural and Pharmacological Interventions in Healthy Obese Subjects

Completed
NCT00212173Not Applicable

Adolescent Weight Management Study

Completed
NCT00402077Phase 2

A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

Completed
NCT00037752Not Applicable

Sibutramine to Reduce Weight Gain and Improve Smoking Cessation Rates

Completed
NCT00729963Phase 4

Sibutramine Versus Continuous Positive Airway Pressure (CPAP)in Obstructive Sleep Apnea (OSA) Patients

Completed
NCT01475019Phase 4

The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS)

Unknown
NCT00993421Phase 2

A Weight Loss Study in Overweight Men and Women

Terminated
NCT00433641Phase 4

Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes

Completed
NCT01184560Not Applicable

Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine

Completed
NCT00330525Phase 2

Pharmacodynamic Effects of Sibutramine on Gastric Function in Obesity

Completed
NCT01023139Not Applicable

"Efficacy in Adolescents of Continued Behavior Modification Following a Six Month Sibutramine-based Weight Management Intervention"

Unknown
NCT00134199Phase 2

A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects

Completed
NCT00941382Phase 3

Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients

Unknown
NCT00537420Phase 2

A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects

Completed
NCT00679653Phase 3

Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives

Completed
NCT00677391Phase 3

Efficacy and Safety Study of Sibutramine in Overweight Non-Diabetic Malaysian Population

Completed
NCT00261911Phase 3

A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety.

Completed
NCT00402584Phase 3

A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder

Completed

Drug Details

Intervention Type
DRUG
Total Trials
22